関節リウマチ, 乾癬性関節炎, 強直性脊椎炎, X線基準を満たさない体軸型脊椎関節炎におけるウパダシチニブ開発臨床試験における悪性腫瘍
Rheumatol Ther 2023;11(1):97–112 doi 10.1007/s40744-023-00621-6
Rates of malignancy were similar between upadacitinib, adalimumab, and MTX. They were also consistent across RA, PsA, AS and nr-axSpA. A dose-dependent increased rate of NMSC was observed with upadacitinib in RA. For RA and PsA, being older (≥65 years) and male was associated with
an increased risk of malignancy excluding NMSC.
Data were pooled from 11 Phase 3 upadacitinib trials, six for RA, two for PsA, two for AS, and one for nr-axSpA. TEAEs were reported as exposure-adjusted event rates (events/100 patient-years), and HRs were used to identify risk factors.
Keywords:
